A lthough interventional radiology (IR) procedures are minimally invasive compared with conven tional surgery, the increasing complexity of the procedures is being accom panied by increasing invasiveness, making ra diologists aware of the importance of sedation and analgesia. The achievement of adequate sedation and analgesia during an IR proce dure is essential [1, 2] . The most popular se dation and analgesia method for IR proce dures involves a combination of fentanyl and midazolam [3] [4] [5] [6] . Although this method is accepted as safe and effective, some reports [7] [8] [9] have emphasized the risks of respiratory and cardiovascular side effects. Studies of remifentanil, a potent opioid agonist with rap id onset (1-2 minutes) and a short duration of action (5-7 minutes), have shown this agent is a safe and effective analgesic drug for many invasive procedures [10] [11] [12] [13] [14] [15] . We investigated whether remifentanil is suitable for IR. We re port on our experience with remifentanil and on its safety and effectiveness during one of OBJECTIVE. The purpose of this study was to evaluate the safety and effectiveness of analgesia with remifentanil for percutaneous transhepatic biliary drainage.
SUBJECTS AND METHODS. Analgesia for percutaneous transhepatic biliary drainage was induced with remifentanil in 186 patients over a 1year period. Remifentanil was adminis tered IV with an infusion pump at 0.1 μg/kg/min as the usual dose and 0.15 μg/kg/min as the maximal dose. Selected patients with severe anxiety also received a 1mg bolus of midazolam. Vital signs, sedation levels, and side effects were checked every 5 minutes during the procedure and recovery. The patients scored their pain subjectively on an 11point numerical rating scale.
RESULTS. The mean total dose of remifentanil was 116.3 μg (range, 32.5-200 μg). Midazolam was administered to 15 patients. Transient bradycardia occurred in 19 patients (10%). Hypotension did not develop in any patient. Respiratory depression occurred in four patients (2%). An appropriate level of sedation was obtained in 182 patients (98%), the modi fied Ramsay score being 2 (n = 164, 88%) or 3 (n = 18, 10%). Fortynine of the patients (26%) indicated no pain (numeric rating, 0), 120 (64%) indicated mild pain (numeric rating, 1-3), and 16 (9%) indicated moderate pain (numeric rating, 4-6). One patient (1%) indicated se vere pain (numeric rating, 7).
CONCLUSION. Remifentanil is safe and highly effective for pain control during per cutaneous transhepatic biliary drainage. This drug is a suitable option for analgesia during painful interventional radiology procedures.
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for at least 4 hours. Each patient's coagulation profile was checked and corrected if possible. No pre medication was administered. Transhepatic punc tures were performed through the right (n = 160, 86%) or left (n = 26, 14%) hepatic lobe under sonographic and fluoro scopic guidance. Initial puncture of the bile duct was made with a 21gauge Chiba needle. If puncture of the bile duct was deemed appropriate, a 0.018inch guidewire (Hair wire, A&A) was advanced through the needle into the bile duct, and a 5French Yellow Sheath (A&A) and 0.035inch guidewire (Radifocus, Terumo) were placed with standard guidewire technique. An 8 to 10French drainage catheter (Dawson Mueller, Cook) was inserted over the guidewire and into a position from which hepatic drainage could be maximized.
Sedation and Analgesia
Procedural sedation and analgesia were per formed with IV remifentanil (Ultiva, Glaxo SmithKline). Remifentanil was prepared in a 0.01 mg/mL solution (1 mg remifentanil mixed with 100 mL normal saline solution) and administered through an infusion pump (Terufusion, Terumo) at a loading dose of 0.1 μg/kg/min, maintenance dose of 0.05 μg/kg/min, and maximal dose of 0.15 μg/kg/min. In most of the cases, the drug was administered through IV tubing used exclusively for remifentanil admini stration. If preexisting IV tubing had to be used, it was filled with the solution up to its exact intraluminal volume and then the infusion was administered.
Infusion was started with the loading dose approximately 5 minutes before the first trans hepatic puncture. If the patient did not report pain during transhepatic puncture, the infusion rate was decreased to the maintenance dose. When the patient reported pain, the infusion rate was in creased to the maximal dose for 2-3 minutes and then was decreased to the maintenance dose. When dizziness, nausea, or vomiting developed, infusion was stopped for approximately 5 minutes. If respiratory depression (oxygen saturation < 90%) developed, infusion was stopped, and the patient was awakened with a loud noise and tactile stimulation. Infusion was maintained until the patient was transferred to the IR recovery room.
For selected patients with severe anxiety before the procedure, a bolus of 1 mg midazolam was injected over approximately 30 seconds into the IV tubing, which was slowly flushed with saline solution. The antagonists of remifentanil (naloxone hydrochloride) and midazolam (flumazenil) were available during all procedures. In addition to IV sedation and analgesia, the patients received local anesthesia with 5-15 mL of 2% lidocaine (Lidocaine, Huons) at the site of puncture. The local anesthetic was injected subcutaneously up to the hepatic capsule.
Patient Monitoring and Evaluation
A designated nurse monitored the patients, checked venous lines, recorded reactions and emotional status, and provided support. No anesthesiologist was present. All patients were continuously monitored with noninvasive mea sure ment of blood pressure (BP) and arterial oxygen saturation during the procedures. All mea surable values were recorded at 5minute intervals during the procedures and were noted on a special protocol sheet along with the drug doses administered. From administration of remifentanil to the end of the procedure, all patients received oxygen (2-3 L/min) through a nasal prong. After the procedure, the patients were transferred to the IR recovery room and were evaluated by the nurse at 5minute intervals for at least 15 minutes until fully awake. Procedurerelated complications and side effects of opioids, such as nausea, vomiting, pruritus, and muscle rigidity, were checked both during and after the procedures [10] .
A modified Ramsay sedation scale [4, 16, 17 ] was used to measure mental status during the procedure (Table 1) . Adequate sedation was defined as a modified Ramsay score of 2 or 3 [16, 17] . After they were fully awake in the IR recovery room, the patients were asked by a radiology resident to indicate on an 11point numerical rating scale the degree of subjective pain felt during the procedure. On the 0-10 pain rating scale, 0 means no pain and 10 means the worst pain possible. The middle of the scale represents moderate pain; 1-3, mild pain; and 7 or greater, severe pain [18, 19] .
Results
All procedures were successfully complet ed in a mean time of 18 minutes (range, 5-40 minutes). The mean total dose of remifen tanil was 116.3 μg (range, 32.5-200 μg). Mi dazolam (1 mg) was administered to 15 pa tients (8%).
During the procedure, the mean mini mum heart rate was 74 beats/min and the mean maximum heart rate was 86 beats/ min. The heart rate changed more than 20% of the initial rate in 12 patients (6%), in creasing in five patients and decreasing in seven patients. Transient bradycardia (heart rate < 60 beats/min) occurred in 19 patients (10%). Two patients (1%) needed a bolus of 0.5 mg of atropine sulfate (Jeil) for resolu tion of bradycardia. The mean preprocedural systolic BP was 131 mm Hg and the diastol ic BP was 80 mm Hg. In six patients (3%) in whom systolic blood pressure was greater than 170 mm Hg before the procedure, a bo lus of 1 mg nicardipine (Perdipine, DongA) was infused by titration. The mean prepro cedural systolic BP was 131 mm Hg, and the diastolic BP was 78 mm Hg. In 11 patients (6%), the systolic BP decreased more than 20% of the initial BP after administration of remifentanil alone (n = 7, 4%) or with nicar dipine (n = 4, 2%). Hypotension (systolic BP < 100 mm Hg) did not develop in any patient. In six patients (3%), arterial oxygen satura tion decreased to 90% or less as a result of respiratory depression (n = 4) or snoring (n = 1). Respiratory depression resolved without pharma cologic reversal soon after cessation of remifentanil administration.
The mean modified Ramsay sedation score was 2.39 (range, 2-5) during the procedure. The distribution of scores is summarized in Table 2 . An appropriate level of sedation, de fined as a modified Ramsay score of 2 (n = 164, 88%) or 3 (n = 18, 10%) was obtained with remifentanil alone (n = 168, 90%) or in combination with midazolam (n = 14, 8%). Four patients (2%) were deeply sedated, three with a score of 4 and one with a score of 5. Mi dazolam and remifentanil were administered to one patient with a score of 5 (one [7%] of the 15 patients who received midazolam).
The mean pain score during the proce dure, summarized in Table 3 , was 1.36, mild No major procedurerelated complications occurred. Seven patients (4%) experienced shivering with a chilling sensation immedi ately after the procedure. Shivering was well controlled in most of these patients with con servative treatment that included administra tion of meperidine (Pethidine, BCWP). Fif teen patients (8%) had nausea during or immediately after the procedure. Nausea was well controlled in all patients by cessa tion of the drug infusion only (n = 6, 3%) or with IV injection of 10 mg metoclopramide (Macperan, Dongwha) (n = 9, 5%). No pru ritus or muscle rigidity occurred.
Discussion
Percutaneous transhepatic biliary drainage is one of the most painful IR procedures and requires high levels of sedation and analgesia. Inadequate sedation and analgesia can induce anxiety, deep respiration, and uncontrollable motion of the patient during the procedure, which can cause difficulty with or even failure of the procedure. Desirable characteristics for procedural sedative drugs for IR include rapid onset of action, short duration of drug effect, rapid recovery time, reversibility with anti dote, reduction of patient anxiety, preserva tion of patient abilities, and few adverse effects, particularly disturbances of cardio vascular and respiratory function.
Fentanyl is a potent, synthetic opioid narcot ic that has a rapid onset of action (usually < 3 minutes and rarely up to 10 minutes) and a short duration of effect (40 minutes at lower doses). It is metabolized in the liver and excret ed in the urine. It produces a potent analgesic effect with few cardiovascular side effects. At higher doses, however, fentanyl can induce re spiratory depression and spontaneous respira tion block by depressing the ventilatory re sponse to carbon dioxide. Because fentanyl has no anxiolytic or sedative effects at low doses, concurrent administration of a pure sedative, most commonly midazolam, is recommended.
Fentanyl and midazolam are titrated easily and are widely used for short painful proce dures. The most serious disadvantage of this combination is the risk of cardiac and respira tory depression. The combination of fentanyl and midazolam has been associated with inci dences of hypoxemia and apnea as high as 25% [7] [8] [9] . Other disadvantages of the combi nation of fentanyl and midazolam are unpre dictable variability in the effective doses among individuals and the requirement for a longer halflife for longduration infusions.
Remifentanil is a potent selective μopioid receptor agonist with analgesic potency ap proximately 20-30 times as great as that of alfentanil. The introduction of a methyl ester group to the Nacyl side chain of the piperi dine ring increases susceptibility to hydro lytic metabolism by nonspecific tissue and blood esterases. Because nonspecific esteras es are involved in multiple steps of human cell metabolism, no organ failure has been identified that can cause reduced breakdown of remifentanil. The major metabolic prod uct is remifentanil acid, which is a relatively inactive carboxylic acid metabolite with only 1/300-1/4,600 the activity of remifentanil, and it should not have any effect at clinical doses of remifentanil [10, 11] .
Because of its unique pharmacologic properties, remifentanil is characterized by rapid and uniform clearance and highly pre dictable onset and offset of effect. Remifen tanil has a terminal halflife of 10-20 min utes, and its contextsensitive halflife time, that is, the time to reach a 50% decease in ef fective site concentration after infusion is stopped, is 3-4 minutes regardless of the du ration of infusion. In contrast, other μopioid agonists have much longer contextsensitive halflife times, which result in accumulation and considerable prolongation of effect with increased duration of infusion [10, 11] .
Because of the presence of glycine in the formulation, remifentanil is contraindicated for epidural or intrathecal administration. It also is contraindicated for use in patients with known hypersensitivity to fentanyl analogues. Innumerable drugs can attenuate the adverse effects associated with remifentanil in high blood concentrations. At appropriate blood concentrations, these adverse effects can be reversed by reduction of the rate of infusion of remifentanil or by administration of fluids. IV administration of an opioid antagonist such as naloxone can be used as a specific antidote to manage severe respiratory depression and muscle rigidity. Respiratory depression from overdosage of remifentanil is not expected to last longer than that caused by the opioid an tagonist naloxone. Reversal of the opioid ef fects can lead to acute pain and sympathetic hyperactivity, which require appropriate pain control [10, 11] .
Moderate sedation or repression of con sciousness, during which patients respond purposefully to verbal commands either alone or accompanied by light tactile stimulation, appears to be an appropriate level of sedation for most percutaneous interventional proce dures. In this study, moderate sedation (Ram say score 2 or 3) was achieved with remifen tanil alone in 90% of the patients. Midazolam was added for one of the deeply sedated pa tients, who was fully awake within 5 minutes of cessation of remifentanil infusion. Antag onists for opioids and benzodiazepine were not needed by any patient.
The analgesic effect of remifentanil was ex cellent during the procedure. According to the numerical rating scale pain score, which was checked in the IR recovery room after the pro cedure, most patients indicated no pain (26%) or mild pain (64%). Although the other pa tients indicated moderate (9%) or severe (1%) pain at the time of score checking, the patients' conditions were stable and the patients did not report substantial pain during the procedure. Because remifentanil has a very short recovery period, sudden discontinuation of delivery, ei ther intentional or inadvertent, can result in sudden onset of pain. Thus postprocedural pain management with a potent antipyretic an algesic or a small amount of a longacting opi oid should be considered before cessation of remifentanil administration. 
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The hemodynamic response to remifenta nil is similar to that of other μopioid recep tor agonists, that is, mild bradycardia and a 15-20% decrease in arterial BP. In this study, marked change (> 20% of the initial rate) in heart rate occurred in 6% of the patients: an increase in 2% and a decrease in 4%. Systol ic BP decreased more than 20% in 6% of the patients; one half of the increases appeared to be caused by antihypertensive drugs rath er than an effect of remifentanil alone. Al though the vital sign records showed no hy potension in any patient, the frequency of hypotension and decreases in BP might have been underestimated because BP recordings were intermittent (every 5 minutes) whereas heart rate and oxygen saturation were moni tored continuously.
In patients who are not intubated, remifen tanil produces respiratory depression in a dosedependent manner, so continuous moni toring of oxygen saturation is mandatory. For tunately, because of a lack of accumulation, this effect is not expected to last for more than 10-15 minutes after discontinuation of infu sion. Administration of supplemental oxygen through a nasal prong or face mask is manda tory for patients who are not intubated. In this study, respiratory depression (oxygen satura tion < 90%) occurred in 3% of patients, even with supplemental oxygen. These patients re covered in response to a loud voice and tactile stimulation within 5-10 minutes of discontin uation of remifentanil infusion. Pharmaco logic reversal agents for opioids or benzodiaz epine were not needed by any patient.
The disadvantages of remifentanil are its narrow safety margin and the low total in fused volume. Accidental overdose of the drug can cause respiratory depression and respiratory arrest. The nursing staff must be informed that when remifentanil is adminis tered through preexisting long IV tubing, the intraluminal volume of the tubing must be considered. Furthermore, when administra tion of remifentanil is discontinued, the infu sion line must be removed to prevent unin tended administration of a remifentanil bolus many hours later when the infusion line is re used. Other disadvantages are lack of anxi olytic effect and time spent preparing the ap propriate solution and setting up an infusion pump. Remifentanil causes adverse effects typical of μopioids, that is, nausea, vomit ing, pruritus, and muscle rigidity.
Although the incidence of nausea and vomiting varies, comparison with use of fen tanyl in patients undergoing eye surgery [20] [21] [22] revealed a lower frequency of post operative nausea with remifentanil (8%) than with fentanyl (54%). The incidence of nau sea (8%) was similar to that in other studies, and nausea was well controlled with conser vative treatment, including metoclopramide. Postprocedural shivering (6%), which can be partly due to biliary sepsis, developed with an incidence similar to that recorded previ ously [23] . Thoracic and muscle rigidity can occur when higher doses of a rapidonset opioid are injected; pruritus did not develop in this study.
This study was limited by its singlearm nonrandomized design and lack of data com paring our results with those of others using fentanyl and midazolam for sedation. We conclude, however, that continuous infusion of remifentanil, which has potent analgesic and mild sedative effects as a single agent and the unique pharmacologic properties of rapid and predictable onset without accumu lation, can be used safely and effectively for painful IR procedures, including percutane ous transhepatic biliary drainage.
